Scribe Therapeutics, Inc. (SCTX) SEC filings
SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.36−0.63 (-3.71%)
Close on Nov 13, 2026Market cap $309.72MP/E –Yield –
SEC filings
5 of Scribe Therapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Sep 30, 2026 | Nov 12, 2026 | SEC EDGAR |
| Current report | 8-K | Nov 12, 2026 | Nov 12, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Sep 2, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 2, 2026 | Sep 2, 2026 | SEC EDGAR |
| Current report | 8-K | Jul 27, 2026 | Jul 27, 2026 | SEC EDGAR |
See a number that looks wrong?